24 research outputs found
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease
An Image-Based High-Content Screening Assay for Compounds Targeting Intracellular Leishmania donovani Amastigotes in Human Macrophages
Leishmaniasis is a tropical disease threatening 350 million people from endemic regions. The available drugs for treatment are inadequate, with limitations such as serious side effects, parasite resistance or high cost. Driven by this need for new drugs, we developed a high-content, high-throughput image-based screening assay targeting the intracellular amastigote stage of different species of Leishmania in infected human macrophages. The in vitro infection protocol was adapted to a 384-well-plate format, enabling acquisition of a large amount of readouts by automated confocal microscopy. The reading method was based on DNA staining and required the development of a customized algorithm to analyze the images, which enabled the use of non-modified parasites. The automated analysis generated parameters used to quantify compound activity, including infection ratio as well as the number of intracellular amastigote parasites and yielded cytotoxicity information based on the number of host cells. Comparison of this assay with one that used the promastigote form to screen 26,500 compounds showed that 50% of the hits selected against the intracellular amastigote were not selected in the promastigote screening. These data corroborate the idea that the intracellular amastigote form of the parasite is the most appropriate to be used in primary screening assay for Leishmania
Antileishmanial High-Throughput Drug Screening Reveals Drug Candidates with New Scaffolds
Drugs currently available for leishmaniasis treatment often show parasite resistance, highly toxic side effects and prohibitive costs commonly incompatible with patients from the tropical endemic countries. In this sense, there is an urgent need for new drugs as a treatment solution for this neglected disease. Here we show the development and implementation of an automated high-throughput viability screening assay for the discovery of new drugs against Leishmania. Assay validation was done with Leishmania promastigote forms, including the screening of 4,000 compounds with known pharmacological properties. In an attempt to find new compounds with leishmanicidal properties, 26,500 structurally diverse chemical compounds were screened. A cut-off of 70% growth inhibition in the primary screening led to the identification of 567 active compounds. Cellular toxicity and selectivity were responsible for the exclusion of 78% of the pre-selected compounds. The activity of the remaining 124 compounds was confirmed against the intramacrophagic amastigote form of the parasite. In vitro microsomal stability and cytochrome P450 (CYP) inhibition of the two most active compounds from this screening effort were assessed to obtain preliminary information on their metabolism in the host. The HTS approach employed here resulted in the discovery of two new antileishmanial compounds, bringing promising candidates to the leishmaniasis drug discovery pipeline
Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong
Use of pneumococcal conjugate vaccines (PCVs) has greatly reduced the incidence of invasive pneumococcal disease (IPD). V114 (VAXNEUVANCE™, Merck Sharp & Dohme Corp. a subsidiary of Merck & Co. Inc. Kenilworth, NJ, USA) is a 15-valent PCV currently approved in adults in the United States, containing the 13 serotypes in licensed PCV13 and 2 additional serotypes (22F and 33F) which are important contributors to residual pneumococcal disease. This study quantified the health and economic burden of IPD attributable to V114 serotypes in hypothetical birth cohorts from Korea and Hong Kong. A Markov model was used to estimate the case numbers and costs of IPD in unvaccinated birth cohorts over 20 years. The model was applied to 3 scenarios in Korea (pre-PCV7, pre-PCV13, and post-PCV13) and to 2 scenarios in Hong Kong (pre-PCV7 and post-PCV13). For Korea, the model predicted 62, 26, and 8 IPD cases attributable to V114 serotypes in the pre-PCV7, pre-PCV13, and post-PCV13 scenarios, respectively. Costs of V114-type IPD fell from .212 million post-PCV13. For Hong Kong, the model estimated 62 V114-associated IPD cases in the pre-PCV7 scenario and 46 in the post-PCV13 scenario. Costs attributed to all V114 serotypes were 1.726 million in the pre-PCV7 and post-PCV13 periods, respectively. Vaccine-type serotypes are predicted to cause continuing morbidity and cost in Korea (19A) and Hong Kong (3 and 19A). New pediatric pneumococcal vaccines must continue to protect against serotypes in licensed vaccines to maintain disease reduction, while extending coverage to non-vaccine serotypes
Phenolic Constituents of Medicinal Plants with Activity against Trypanosoma brucei
Neglected tropical diseases (NTDs) affect over one billion people all over the world. These diseases are classified as neglected because they impact populations in areas with poor financial conditions and hence do not attract sufficient research investment. Human African Trypanosomiasis (HAT or sleeping sickness), caused by the parasite Trypanosoma brucei, is one of the NTDs. The current therapeutic interventions for T. brucei infections often have toxic side effects or require hospitalization so that they are not available in the rural environments where HAT occurs. Furthermore, parasite resistance is increasing, so that there is an urgent need to identify novel lead compounds against this infection. Recognizing the wide structural diversity of natural products, we desired to explore and identify novel antitrypanosomal chemotypes from a collection of natural products obtained from plants. In this study, 440 pure compounds from various medicinal plants were tested against T. brucei by in a screening using whole cell in vitro assays. As the result, twenty-two phenolic compounds exhibited potent activity against cultures of T. brucei. Among them, eight compounds—4, 7, 11, 14, 15, 18, 20, and 21—showed inhibitory activity against T. brucei, with IC50 values below 5 µM, ranging from 0.52 to 4.70 μM. Based on these results, we attempt to establish some general trends with respect to structure-activity relationships, which indicate that further investigation and optimization of these derivatives might enable the preparation of potentially useful compounds for treating HAT
An Image-Based Algorithm for Precise and Accurate High Throughput Assessment of Drug Activity against the Human Parasite <i>Trypanosoma cruzi</i>
<div><p>We present a customized high content (image-based) and high throughput screening algorithm for the quantification of <i>Trypanosoma cruzi</i> infection in host cells. Based solely on DNA staining and single-channel images, the algorithm precisely segments and identifies the nuclei and cytoplasm of mammalian host cells as well as the intracellular parasites infecting the cells. The algorithm outputs statistical parameters including the total number of cells, number of infected cells and the total number of parasites per image, the average number of parasites per infected cell, and the infection ratio (defined as the number of infected cells divided by the total number of cells). Accurate and precise estimation of these parameters allow for both quantification of compound activity against parasites, as well as the compound cytotoxicity, thus eliminating the need for an additional toxicity-assay, hereby reducing screening costs significantly. We validate the performance of the algorithm using two known drugs against <i>T.cruzi</i>: Benznidazole and Nifurtimox. Also, we have checked the performance of the cell detection with manual inspection of the images. Finally, from the titration of the two compounds, we confirm that the algorithm provides the expected half maximal effective concentration (EC50) of the anti-<i>T. cruzi</i> activity.</p></div
Image enhancement process.
<p>(<b>A</b>) Original image of maximum intensity 6461. (<b>B</b>) Cumulative histogram of intensity. The maximum intensity is rescaled to the intensity of higher 1% cumulative intensity level. (<b>C</b>) Intensity equalized image. The maximum intensity has decreased to 1805. (<b>D</b>) Estimated shading map of (C). (<b>E</b>) Biased illumination was corrected from (C). The numbers in the boxes of (C) and (E) are average intensities of nuclei in the yellow dashed circles.</p
In Vitro and in Vivo Activity of Multitarget Inhibitors against Trypanosoma brucei
We
tested a series of amidine and related compounds against Trypanosoma brucei. The most active compound was
a biphenyldiamidine that had an EC<sub>50</sub> of 7.7 nM against
bloodstream-form parasites. There was little toxicity against two
human cell lines with CC<sub>50</sub> > 100 μM. There was
also good in vivo activity in a mouse model of infection with 100%
survival at 3 mg/kg i.p. The most potent lead blocked replication
of kinetoplast DNA (k-DNA), but not nuclear DNA, in the parasite.
Some compounds also inhibited the enzyme farnesyl diphosphate synthase
(FPPS), and some were uncouplers of oxidative phosphorylation. We
developed a computational model for T. brucei cell growth inhibition (<i>R</i><sup>2</sup> = 0.76) using
DNA Δ<i>T</i><sub>m</sub> values for inhibitor binding
combined with T. brucei FPPS IC<sub>50</sub> values. Overall, the results suggest that it may be possible
to develop multitarget drug leads against T. brucei that act by inhibiting both k-DNA replication and isoprenoid biosynthesis
Nuclei region segmentation results for examples of difficult cases.
<p>(<b>A</b>) Parasites are too close to a nucleus. (<b>B</b>) Nucleus intensity is too high. (<b>C</b>) Parasites intensities are too high. (<b>Second row</b>) Parasite-removal images by the proposed method. (<b>Third row</b>) Nuclei masks by Otsu's thresholding method applied to the second row images. (<b>Fourth row</b>) Boundaries of segmented nuclei regions (green contours) overlapped to the original images.</p
<i>T. cruzi</i> fluorescence images.
<p>(<b>A</b>) Negative control image (infected host cells). (<b>B</b>) Positive control image (uninfected host cells). (<b>C</b>) 3D surface plot of infected host cells in the yellow boxed region of (A). (<b>D</b>) 3D surface plot of uninfected host cells in the yellow boxed region of (B). Note that intensity ranges of (A) and (B) are rescaled for enhanced visibility.</p